Guo Yuxin, Hu Zhiyuan, Wang Zihua
CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.
Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Front Mol Neurosci. 2021 Dec 23;14:778955. doi: 10.3389/fnmol.2021.778955. eCollection 2021.
Alzheimer's disease (AD) is one of the most common neurodegenerative diseases with irreversible damage of the brain and a continuous pathophysiological process. Early detection and accurate diagnosis are essential for the early intervention of AD. Precise detection of blood biomarkers related to AD could provide a shortcut to identifying early-stage patients before symptoms. In recent years, targeting peptides or peptoids have been chosen as recognition elements in nano-sensors or fluorescence detection to increase the targeting specificity, while peptide-based probes were also developed considering their specific advantages. Peptide-based sensors and probes have been developed according to different strategies, such as natural receptors, high-throughput screening, or artificial design for AD detection. This review will briefly summarize the recent developments and trends of AD diagnosis platforms based on peptide and peptoid as recognition elements and provide insights into the application of peptide and peptoid with different sources and characteristics in the diagnosis of AD biomarkers.
阿尔茨海默病(AD)是最常见的神经退行性疾病之一,会对大脑造成不可逆损伤,且是一个持续的病理生理过程。早期检测和准确诊断对于AD的早期干预至关重要。精确检测与AD相关的血液生物标志物可为在症状出现前识别早期患者提供一条捷径。近年来,靶向肽或类肽已被选作纳米传感器或荧光检测中的识别元件,以提高靶向特异性,同时也鉴于其特定优势开发了基于肽的探针。基于肽的传感器和探针已根据不同策略开发出来,如天然受体、高通量筛选或用于AD检测的人工设计。本综述将简要总结基于肽和类肽作为识别元件的AD诊断平台的最新进展和趋势,并深入探讨不同来源和特性的肽和类肽在AD生物标志物诊断中的应用。